: Clinical parameters of melanoma patients
| Clinical features | ZEB1 score (IF) | Statistic | |||
| Total | ZEB1 low | ZEB1 high | |||
| Sex | Female, n (%) | 22 (37) | 15 (36) | 6 (50) | Fisher’s exact test, ns |
| Male, n (%) | 38 (63) | 27 (64) | 6 (50) | ||
| Age | Median (range) | 62 (24–85) | 60 (24–85) | 68 (36–82) | t-test, ns |
| Cutaneous melanoma | Primary, n (%) | 30 (50) | 22 (52) | 4 (33) | Fisher’s exact test, ns |
| Metastasis, n (%) | 30 (50) | 20 (48) | 8 (67) | ||
| T stage (primary) | T1a | 1 | 0 | χ2, ns | |
| T1b | 1 | 0 | |||
| T2a | 3 | 0 | |||
| T2b | 1 | 0 | |||
| T3a | 3 | 1 | |||
| T3b | 2 | 1 | |||
| T4a | 2 | 0 | |||
| T4b | 9 | 2 | |||
| Breslow (mm) (primary) | Median | 4.35 | 4.25 | 4.35 | t-test, ns |
| BRAF/NRAS mutation status, n (%) | BRAF | 23 (38) | 14 (33) | 5 (42) | χ2, ns |
| NRAS | 11 (18) | 10 (24) | 1 (8) | ||
| WT | 26 (43) | 18 (43) | 6 (50) | ||
IF, immunofluorescence.